Darell Bigner
55Patents
12h-index
61Co-inventors
87Inventor score
Filing activity: Dec 17, 1990 → Jul 5, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5212290A | Antibodies specific for type II mutant EGTR | Emerging Cross-Sectional Technologies | 82 | Expired |
| US5624659A | Method of treating brain tumors expressing tenascin | Human Necessities | 47 | Expired |
| US5401828A | Structural alterations of the EGF receptor gene in human gliomas | Emerging Cross-Sectional Technologies | 26 | Expired |
| US6127126A | Method for diagnosing glioma associated with structural alterations of the EGF receptor gene in human tumors | Chemistry; Metallurgy | 23 | Expired |
| US5981725A | Structural alterations of the EGF receptor gene in human tumors | Chemistry; Metallurgy | 23 | Expired |
| US5558852A | Methods of treating melanomas and gliomas with monoclonal antibody Me1-14 | Human Necessities | 22 | Expired |
| US7129332B2 | Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof | Chemistry; Metallurgy | 20 | Expired |
| US10704108B2 | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | Physics | 19 | Active |
| US5814317A | Structural alterations of the EGF receptor gene in human gliomas | Emerging Cross-Sectional Technologies | 18 | Expired |
| US5710010A | Assays for the presence of a mutant EGF receptor | Emerging Cross-Sectional Technologies | 18 | Expired |
| US8685660B2 | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | Physics | 17 | Active |
| US6455498B1 | Structural alterations of the EGF receptor genes in human tumors | Chemistry; Metallurgy | 17 | Expired |
| US6503503B1 | Allogeneic cellular vaccine | Human Necessities | 12 | Expired |
| US9353418B2 | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | Physics | 12 | Active |
| US5695751A | Enhancing delivery of large neutral amino acid drugs | Human Necessities | 11 | Expired |
| US8541568B2 | Compositions and methods using siRNA molecules for treatment of gliomas | Chemistry; Metallurgy | 10 | Active |
| US10837064B2 | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | Physics | 9 | Active |
| US8039593B2 | Antibodies and immunotoxins that target human glycoprotein NMB | Chemistry; Metallurgy | 9 | Active |
| US9249217B2 | Bispecific EGFRvIII x CD3 antibody engaging molecules | Chemistry; Metallurgy | 6 | Active |
| US10894987B2 | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | Physics | 3 | Active |
| US5523084A | Enhancing the anti-tumor effect of melphalan by prior administration of L-amino acid oxidase with or without intermediate administration of anti-L-amino acid oxidase antibody | Chemistry; Metallurgy | 3 | Expired |
| US9873917B2 | Oligodendroglioma drive genes | Chemistry; Metallurgy | 2 | Active |
| US10053514B2 | Human bispecific EGFRvIII and CD3 antibody engaging molecules | Chemistry; Metallurgy | 2 | Active |
| US10398743B2 | Oncolytic poliovirus for human tumors | Emerging Cross-Sectional Technologies | 2 | Active |
| US10799543B2 | Oncolytic poliovirus for human tumors | Emerging Cross-Sectional Technologies | 2 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.